Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.
Camille AllardDaniela CotaCarmelo QuartaPublished in: Drugs (2023)
The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity holds great promise for improving glycaemic control and weight management. Unimolecular dual and triple agonists targeting multiple gut hormone-related pathways are currently in clinical trials, with recent evidence supporting their efficacy. However, significant knowledge gaps remain regarding the biological mechanisms and potential adverse effects associated with these multi-target agents. The mechanisms underlying the therapeutic efficacy of GLP-1 receptor-based multi-agonists remain somewhat mysterious, and hidden threats may be associated with the use of gut hormone-based polyagonists. In this review, we provide a critical analysis of the benefits and risks associated with the use of these new drugs in the management of obesity and diabetes, while also exploring new potential applications of GLP-1-based pharmacology beyond the field of metabolic disease.
Keyphrases
- type diabetes
- weight loss
- weight gain
- clinical trial
- insulin resistance
- metabolic syndrome
- human health
- healthcare
- cardiovascular disease
- high fat diet induced
- body mass index
- randomized controlled trial
- physical activity
- risk assessment
- adipose tissue
- drug delivery
- binding protein
- machine learning
- climate change
- phase ii
- open label
- double blind